Cargando…
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private s...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280938/ https://www.ncbi.nlm.nih.gov/pubmed/34111271 http://dx.doi.org/10.1093/infdis/jiab305 |
| _version_ | 1783722745187532800 |
|---|---|
| author | Hall, Matthew D Anderson, James M Anderson, Annaliesa Baker, David Bradner, Jay Brimacombe, Kyle R Campbell, Elizabeth A Corbett, Kizzmekia S Carter, Kara Cherry, Sara Chiang, Lillian Cihlar, Tomas de Wit, Emmie Denison, Mark Disney, Matthew Fletcher, Courtney V Ford-Scheimer, Stephanie L Götte, Matthias Grossman, Abigail C Hayden, Frederick G Hazuda, Daria J Lanteri, Charlotte A Marston, Hilary Mesecar, Andrew D Moore, Stephanie Nwankwo, Jennifer O O’Rear, Jules Painter, George Singh Saikatendu, Kumar Schiffer, Celia A Sheahan, Timothy P Shi, Pei-Yong Smyth, Hugh D Sofia, Michael J Weetall, Marla Weller, Sandra K Whitley, Richard Fauci, Anthony S Austin, Christopher P Collins, Francis S Conley, Anthony J Davis, Mindy I |
| author_facet | Hall, Matthew D Anderson, James M Anderson, Annaliesa Baker, David Bradner, Jay Brimacombe, Kyle R Campbell, Elizabeth A Corbett, Kizzmekia S Carter, Kara Cherry, Sara Chiang, Lillian Cihlar, Tomas de Wit, Emmie Denison, Mark Disney, Matthew Fletcher, Courtney V Ford-Scheimer, Stephanie L Götte, Matthias Grossman, Abigail C Hayden, Frederick G Hazuda, Daria J Lanteri, Charlotte A Marston, Hilary Mesecar, Andrew D Moore, Stephanie Nwankwo, Jennifer O O’Rear, Jules Painter, George Singh Saikatendu, Kumar Schiffer, Celia A Sheahan, Timothy P Shi, Pei-Yong Smyth, Hugh D Sofia, Michael J Weetall, Marla Weller, Sandra K Whitley, Richard Fauci, Anthony S Austin, Christopher P Collins, Francis S Conley, Anthony J Davis, Mindy I |
| author_sort | Hall, Matthew D |
| collection | PubMed |
| description | The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development. |
| format | Online Article Text |
| id | pubmed-8280938 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82809382021-08-10 Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit Hall, Matthew D Anderson, James M Anderson, Annaliesa Baker, David Bradner, Jay Brimacombe, Kyle R Campbell, Elizabeth A Corbett, Kizzmekia S Carter, Kara Cherry, Sara Chiang, Lillian Cihlar, Tomas de Wit, Emmie Denison, Mark Disney, Matthew Fletcher, Courtney V Ford-Scheimer, Stephanie L Götte, Matthias Grossman, Abigail C Hayden, Frederick G Hazuda, Daria J Lanteri, Charlotte A Marston, Hilary Mesecar, Andrew D Moore, Stephanie Nwankwo, Jennifer O O’Rear, Jules Painter, George Singh Saikatendu, Kumar Schiffer, Celia A Sheahan, Timothy P Shi, Pei-Yong Smyth, Hugh D Sofia, Michael J Weetall, Marla Weller, Sandra K Whitley, Richard Fauci, Anthony S Austin, Christopher P Collins, Francis S Conley, Anthony J Davis, Mindy I J Infect Dis NIH Virtual SARS-CoV-2 Supplement The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development. Oxford University Press 2021-06-10 /pmc/articles/PMC8280938/ /pubmed/34111271 http://dx.doi.org/10.1093/infdis/jiab305 Text en Published by Oxford University Press for the Infectious Diseases Society of America 2021. This work is written by (a) US Government employee(s) and is in the public domain in the US. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
| spellingShingle | NIH Virtual SARS-CoV-2 Supplement Hall, Matthew D Anderson, James M Anderson, Annaliesa Baker, David Bradner, Jay Brimacombe, Kyle R Campbell, Elizabeth A Corbett, Kizzmekia S Carter, Kara Cherry, Sara Chiang, Lillian Cihlar, Tomas de Wit, Emmie Denison, Mark Disney, Matthew Fletcher, Courtney V Ford-Scheimer, Stephanie L Götte, Matthias Grossman, Abigail C Hayden, Frederick G Hazuda, Daria J Lanteri, Charlotte A Marston, Hilary Mesecar, Andrew D Moore, Stephanie Nwankwo, Jennifer O O’Rear, Jules Painter, George Singh Saikatendu, Kumar Schiffer, Celia A Sheahan, Timothy P Shi, Pei-Yong Smyth, Hugh D Sofia, Michael J Weetall, Marla Weller, Sandra K Whitley, Richard Fauci, Anthony S Austin, Christopher P Collins, Francis S Conley, Anthony J Davis, Mindy I Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit |
| title | Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit |
| title_full | Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit |
| title_fullStr | Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit |
| title_full_unstemmed | Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit |
| title_short | Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit |
| title_sort | report of the national institutes of health sars-cov-2 antiviral therapeutics summit |
| topic | NIH Virtual SARS-CoV-2 Supplement |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280938/ https://www.ncbi.nlm.nih.gov/pubmed/34111271 http://dx.doi.org/10.1093/infdis/jiab305 |
| work_keys_str_mv | AT hallmatthewd reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT andersonjamesm reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT andersonannaliesa reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT bakerdavid reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT bradnerjay reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT brimacombekyler reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT campbellelizabetha reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT corbettkizzmekias reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT carterkara reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT cherrysara reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT chianglillian reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT cihlartomas reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT dewitemmie reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT denisonmark reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT disneymatthew reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT fletchercourtneyv reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT fordscheimerstephaniel reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT gottematthias reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT grossmanabigailc reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT haydenfrederickg reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT hazudadariaj reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT lantericharlottea reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT marstonhilary reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT mesecarandrewd reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT moorestephanie reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT nwankwojennifero reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT orearjules reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT paintergeorge reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT singhsaikatendukumar reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT schifferceliaa reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT sheahantimothyp reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT shipeiyong reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT smythhughd reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT sofiamichaelj reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT weetallmarla reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT wellersandrak reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT whitleyrichard reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT faucianthonys reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT austinchristopherp reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT collinsfranciss reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT conleyanthonyj reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit AT davismindyi reportofthenationalinstitutesofhealthsarscov2antiviraltherapeuticssummit |